Date: 2013-10-31
Type of information: Grant
Company: Ablynx (Belgium)
Investors: Flemish Agency for Innovation by Science and Technology (IWT) (Belgium)
Amount: €1.68 million
Funding type: grant
Planned used: The grant will be used to help advance Ablynx\'s first inhaled Nanobody®, ALX-0171, in infants
Others: * On October 31, 2013, Ablynx has announced that it has received notice of a €1.68 million in grant funding from the Flemish Agency for Innovation by Science and Technology (IWT) to help advance the Company\'s first inhaled Nanobody®, ALX-0171, in infants. The grant funding, which is available over a period of one year, will also be used to explore novel applications of nebulised Nanobodies.
A first Phase I study in healthy volunteers demonstrated that the Nanobody was well-tolerated and had no clinical significant effects on lung function. Furthermore, no dose-limited toxicity, no treatment emergent immunogenicity and no bronchoconstriction occurred. The optimal delivery of the Nanobody through nebulisation has been demonstrated in a reconstructed upper airway anatomical model of a 9-month old baby, showing significant deposition of ALX-0171 in the model infant lung. An additional pre-clinical study and two additional safety studies are currently-on-going with the goal to commence the first-in-infant trial during H2 2014.
Therapeutic area: Infectious diseases - Respiratory diseases
